SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to address neurodegenerative and other CNS diseases. The company focuses on targets that are supported by human biology and which play a critical role in regulating foundation biology, to achieve better probability of success in clinical development. SciNeuro is committed to delivering medicines that can make a difference to improve the lives of patients around the world, transforming scientific discoveries into groundbreaking therapies.
Location: United States, Maryland, Rockville
Employees: 11-50
Total raised: $53M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.12.2025 | - | $53M | - |
Mentions in press and media 3
| Date | Title | Description |
| 04.12.2025 | SciNeuro Pharmaceuticals Lands $53M | ROCKVILLE, MD, SciNeuro Pharmaceuticals today announced the completion of a total of $53 million in equity financing. >> Click here for more funding data on SciNeuro Pharmaceuticals >> To export SciNeuro Pharmaceuticals funding... |
| - | Investors have poured $548 million into neuroscience biotechs this year. Meet the 10 startups that have raised the most cash. | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Neuroscience companies have raised more money from VCs in rec... |
| - | SciNeuro | “Deciphering the Enigma of Brain Disease __NEW - SciNeuro Pharmaceuticals” |